Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
[This article belongs to Volume - 26, Issue - 01]

Investigation of Thyroid dysfunction among hepatitis B & C patients and its association with Interferon therapy

The liver infections are the major cause of increasing mortality rate throughout the world. Liver cirrhosis and hepatocellular carcinoma (HCC) cause an estimated 783,000 and 619,000 deaths per year respectively. Thyroid dysfunction (TD) represents an extra hepatic manifestation of chronic hepatitis C (CHC). Moreover, the currently approved treatment of CHC is often associated with TD. However, it remains debatable if TD is mainly virus or treatment related. The aim of this study was to assess the incidence of TD and to identify its predictors in treated and untreated CHC‑infected patients. Aim of current work was to explore the effect of interferon therapy on the thyroid profile of viral hepatic patients. A total of 150(are those patients who received therapy and 50 is the control group which is given below) HBV and HCV patients who were receiving peg interferon therapy were assessed for the thyroid profile against 50 patients of untreated viral hepatic control group. Add methodology. Thyroid profile was relatively higher in younger patients (20-30 years) as compared to control group. A higher level of thyroid hormone was observed in age group of 20 to 30 (30.71%) among the exploratory and control group. Female patients show slight elevation in thyroid profile in contrast to male patients. The observed value of certain thyroid hormones was hyperthyroidism is about 28% in HCV patients, followed by hypothyroidism 24% and similarly euthyroidism developed in 48% of patients while in HBV patients the hyperthyroidism was noted 35%, hypothyroidism was 21% and euthyroidism was observed 44%.